Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedSep 21, 2025
DataAggregated Company Financials
Companies546
  • 7D1.0%
  • 3M11.5%
  • 1Y-8.1%
  • YTD7.2%

In the last week, Biotech has been flat. As for the longer term, the industry has declined 8.1% in the last year. Looking forward, earnings are forecast to grow by 25% annually.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 21 Sep 2025US$1.1tUS$163.5b-US$18,307,901,758.9716.3x-59.2x6.6x
Tue, 19 Aug 2025US$1.1tUS$163.6b-US$18,805,727,983.0615.6x-57.2x6.6x
Thu, 17 Jul 2025US$964.8bUS$155.8b-US$23,409,909,784.6917.2x-41.2x6.2x
Sat, 14 Jun 2025US$958.5bUS$155.9b-US$23,959,805,126.3116.3x-40x6.1x
Mon, 12 May 2025US$861.1bUS$154.9b-US$24,538,327,634.7316.7x-35.1x5.6x
Wed, 09 Apr 2025US$728.1bUS$118.6b-US$36,894,652,377.2319.3x-19.7x6.1x
Fri, 07 Mar 2025US$848.3bUS$119.0b-US$37,227,382,606.3116.9x-22.8x7.1x
Sun, 02 Feb 2025US$1.0tUS$149.5b-US$26,306,804,829.5717.2x-38.1x6.7x
Tue, 31 Dec 2024US$977.8bUS$149.6b-US$26,368,249,096.0516.9x-37.1x6.5x
Thu, 28 Nov 2024US$1.0tUS$150.0b-US$26,605,248,182.6016.6x-38.7x6.9x
Sat, 26 Oct 2024US$886.8bUS$113.1b-US$36,035,376,152.3020.6x-24.6x7.8x
Mon, 23 Sep 2024US$920.0bUS$113.2b-US$35,983,947,157.4121.9x-25.6x8.1x
Wed, 21 Aug 2024US$905.2bUS$113.2b-US$35,832,221,284.6522.9x-25.3x8x
Fri, 19 Jul 2024US$1.2tUS$164.5b-US$28,050,002,699.2829x-43.2x7.4x
Sun, 16 Jun 2024US$1.2tUS$164.4b-US$28,071,754,707.3727.3x-41.2x7x
Tue, 14 May 2024US$1.1tUS$164.7b-US$26,999,224,352.9423.2x-41.7x6.8x
Thu, 11 Apr 2024US$1.1tUS$164.3b-US$23,371,324,513.6221.4x-48.7x6.9x
Sat, 09 Mar 2024US$1.2tUS$167.3b-US$22,121,973,439.0319x-54x7.1x
Mon, 05 Feb 2024US$1.4tUS$203.9b-US$24,425,425,728.0019.2x-58.9x7.1x
Wed, 03 Jan 2024US$1.4tUS$204.8b-US$22,201,360,571.0021x-63.9x6.9x
Fri, 01 Dec 2023US$1.2tUS$204.7b-US$22,039,871,274.0018.5x-56x6x
Sun, 29 Oct 2023US$1.2tUS$206.6b-US$15,166,070,486.0016.3x-77.7x5.7x
Tue, 26 Sep 2023US$1.3tUS$207.4b-US$12,899,236,949.0017x-97.7x6.1x
Thu, 24 Aug 2023US$1.3tUS$207.6b-US$12,449,828,498.0017.5x-103.1x6.2x
Sat, 22 Jul 2023US$1.2tUS$186.5b-US$16,009,709,300.0012.8x-72x6.2x
Mon, 19 Jun 2023US$1.2tUS$186.3b-US$16,034,836,469.0012.1x-72.3x6.2x
Wed, 17 May 2023US$1.2tUS$191.6b-US$12,334,188,018.0013.3x-93.3x6x
Fri, 14 Apr 2023US$1.2tUS$198.6b-US$3,203,316,182.0014.2x-369.1x6x
Sun, 12 Mar 2023US$1.1tUS$199.3b-US$4,751,094,936.0014.9x-230.3x5.5x
Tue, 07 Feb 2023US$1.2tUS$202.1bUS$1.8b16.4x644.8x5.7x
Thu, 05 Jan 2023US$1.2tUS$203.3bUS$1.6b14.4x711.3x5.7x
Sat, 03 Dec 2022US$1.2tUS$202.6bUS$1.4b15.1x843.3x5.8x
Mon, 31 Oct 2022US$1.1tUS$205.9bUS$7.4b14.3x148.7x5.3x
Wed, 28 Sep 2022US$1.0tUS$205.7bUS$5.5b13.9x186.2x4.9x
Price to Earnings Ratio

186.2x


Total Market Cap: US$1.0tTotal Earnings: US$5.5bTotal Revenue: US$205.7bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average 34.6x202320242025
Current Industry PE
  • Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 6.4x.
Past Earnings Growth
  • Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
  • Revenues have also declined 7.4% per year, which is driving profits down.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market1.49%
Healthcare-0.58%
Biotech0.99%
Biotech0.99%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ABBV AbbVieUS$222.471.9%
+US$7.3b		15.0%PE105.6x
AMGN AmgenUS$285.413.3%
+US$4.9b		-15.4%PE23.2x
REGN Regeneron PharmaceuticalsUS$591.995.7%
+US$3.3b		-48.3%PE13.8x
NTRA NateraUS$181.117.5%
+US$1.7b		41.7%PS12.7x
ONC BeOne MedicinesUS$334.403.1%
+US$1.1b		65.6%PS8.1x

Latest News

BIIB
US$142.50
Biogen
7D
-1.6%
1Y
-28.5%

Expanding Global Healthcare And Diagnostics Infrastructure Will Drive Future Growth

Biogen's modestly reduced consensus price target reflects a balanced analyst view, with optimism around strong Q2 performance, pipeline progress, and portfolio refocusing offset by lingering regulatory overhangs and a muted near-term growth outlook, resulting in a slight decrease in fair value from $171.96 to $170.03. Analyst Commentary Bullish analysts cite strong Q2 performance, particularly from Leqembi and the MS franchise, as well as solid sales across other programs as drivers for raised price targets.
INCY
US$86.53
Incyte
7D
4.1%
1Y
31.6%
VRTX
US$383.12
Vertex Pharmaceuticals
7D
-2.9%
1Y
-17.6%

Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Popularity With Investors Is Under Threat From Overpricing

Sep 19
Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Popularity With Investors Is Under Threat From Overpricing
NTRA
US$181.11
Natera
7D
7.5%
1Y
41.7%
ETNB
US$14.87
89bio
7D
84.3%
1Y
81.6%
REGN
US$591.99
Regeneron Pharmaceuticals
7D
5.7%
1Y
-48.3%

Broad Pipeline And Global Access Will Build Future Success

Regeneron Pharmaceuticals’ price target was raised to $722.20 as analysts cited continued outperformance and growth potential for Dupixent and Eylea, strong late-stage trial results in myasthenia gravis, and reinforced market leadership following competitor setbacks. Analyst Commentary Bullish analysts highlighted ongoing strength and growth potential for Dupixent and Eylea, with market share remaining dominant and robust prospects for Eylea HD.
ONC
US$334.40
BeOne Medicines
7D
3.1%
1Y
65.6%

Oncology Trials And Global Expansion Will Unlock Future Markets

BeOne Medicines’ consensus price target was raised to $367.68, reflecting analyst optimism driven by robust sales growth, positive pipeline updates, profitability, and increased revenue guidance. Analyst Commentary Bullish analysts highlight BeOne Medicines’ broad oncology pipeline and upcoming pivotal data readouts—specifically BTK inhibitor data in mantle cell lymphoma and PD1 inhibitor/anti-HER2 combination results in gastroesophageal cancer—as key drivers for durable growth.
RVMD
US$43.54
Revolution Medicines
7D
-6.5%
1Y
-4.1%
ATYR
US$0.99
aTyr Pharma
7D
-83.5%
1Y
-45.5%
ABBV
US$222.47
AbbVie
7D
1.9%
1Y
15.0%
RNA
US$41.06
Avidity Biosciences
7D
-8.2%
1Y
-7.7%
ALNY
US$453.56
Alnylam Pharmaceuticals
7D
-2.6%
1Y
65.6%
AMGN
US$285.41
Amgen
7D
3.3%
1Y
-15.4%
GILD
US$114.09
Gilead Sciences
7D
-0.4%
1Y
35.9%
MRNA
US$25.24
Moderna
7D
7.4%
1Y
-61.6%

Pipeline Diversification And Regulatory Momentum Will Unlock Future Potential

Moderna’s consensus price target was held at $44.25 as analysts cited declining US vaccine demand, increased regulatory hurdles for flu/COVID combinations, delayed UK deliveries impacting 2025 guidance, and persistent uncertainty around mRNA vaccine approvals. Analyst Commentary Lowered US vaccination trends for both COVID and flu are reducing addressable market expectations for Moderna’s vaccines.
CAI
US$32.58
Caris Life Sciences
7D
-4.3%
1Y
n/a